このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

脳転移に対する放射線療法を受けた患者の神経心理学的変化

2026年11月10日 更新者:National Cancer Institute (NCI)

脳転移に対する放射線療法を受けている患者の神経心理学的結果測定値と予後との関係を評価するパイロット研究

Background:

  • There are no standardized sets of tests to measure changes in neuropsychological functioning in patients treated for brain metastasis (cancer that has spread beyond the original site to the brain).
  • Neuropsychological function has an important effect on quality of life and should be included when determining treatment options.

Objectives:

  • To find out if there is a change in patients cognitive (thinking) and daily functioning after standard radiation treatment for brain metastasis that can be measured with tests.
  • To see if any changes on these tests are related to patients response to radiation therapy.

Eligibility:

- Patients 18 years of age or older who have cancer that has spread to the brain.

Design:

  • Patients receive a 2-week course of radiation therapy to the brain, given daily 5 days a week. Some patients may require stereotactic radiosurgery (an additional boost of radiation therapy to specific sites of brain metastasis).
  • Patients have the following evaluations before and after treatment to determine changes in cognition and functioning:
  • Neuropsychological testing to measure cognitive (thinking) abilities like memory, attention, processing speed, and reading, and fine motor skills.
  • Questionnaires to assess quality of life and daily living skills.
  • Patients have MRI scans and blood and urine tests.
  • At the completion of radiation treatment, patients return to the clinic for follow-up visits at 1, 2, 4, 6, 9 and 12 months for blood and urine tests, physical examination, MRI of the brain, neuropsychological testing and assessments of quality of life and daily living skills.

調査の概要

状態

完了

条件

詳細な説明

Background:

  • Metastatic brain tumors occur more frequently than primary brain tumors and occur in approximately 25 percent of patients who die of cancer each year.
  • The Radiation Therapy Oncology Group (RTOG) developed three prognostic classes using a recursive partitioning analysis (RPA) of a large database. These classes are based on Karnofsky Performance Status (KPS), age and disease status.
  • The RTOG RPA classes do not include neuropsychological function as a measure of outcome.
  • There is no consensus of standardization of test selection to measure changes in neuropsychological functioning in this patient population.
  • Neuropsychological function has an important effect on quality of life and should be included when determining prognosis and treatment options for patients.
  • Neuropsychological functioning is important when determining the effects of treatments and for measuring outcomes in clinical trials.

Objectives:

  • To identify the neuropsychological test scores which detect significant change in neuropsychological functioning in patients receiving radiation therapy for brain metastases.
  • To examine the relationship between neuropsychological function and survival in patients receiving radiation therapy for brain metastases.

Eligibility:

  • Patients aged 18 years and older.
  • Pathologically confirmed primary malignancy with at least one intraparenchymal brain metastasis as identified on brain MRI scan with intravenous contrast.
  • The patient must communicate in English in order to complete the neuropsychological evaluations.

Design:

  • This is a longitudinal study that will administer serial neuropsychological assessments to patients with brain metastases who receive radiation therapy.
  • Patients will undergo a battery of neuropsychological tests prior to radiotherapy (WBRT or WBRT followed by SRS), 2 weeks after completion of radiation therapy, then every 3 months for up to 12 months.
  • The test battery will involve approximately 40 minutes of direct cognitive testing and 15 minutes of questionnaires.

There will be three cohorts of 20 patients each for a total of 60 patients. The three cohorts will be made up of differing histologies and will be sorted on the basis of their RTOG RPA Class.

研究の種類

観察的

入学 (実際)

35

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • National Institutes of Health Clinical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Primary clinical

説明

-INCLUSION CRITERIA:

  1. Patients must be 18 years of age or older.

  2. Pathologically confirmed primary malignancy with at least one intraparenchymal brain metastasis as identified on brain MRI scan with intravenous contrast.

    • Cohort 1 (N=20): KPS greater than 70; Age less than or equal to 65; controlled primary tumor and no extracranial metastases.
    • Cohort 2 (N=20): KPS greater than 70 and at least one of the following: age greater than 65, uncontrolled or synchronous primary disease, or extracranial metastases
    • Cohort 3 (N=20): KPS less than 70
  3. Patient must have a primary medical or surgical oncologist in the community or at NCI who is willing to collaborate with the ROB staff in the clinical management of the patient.

  4. All patients must sign a document of informed consent indicating their understanding of the investigational nature and the risks of this study BEFORE any of the protocol related studies are preformed (this does not include routine laboratory tests or imaging studies required to establish eligibility).

  5. Subjects of childbearing or child- fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while they are being treated on this study.

EXCLUSION CRITERIA:

  1. Cognitively impaired patients who cannot give informed consent, including patients assigned a power of attorney for medical decisions.

  2. Inability to communicate in the English language.

  3. Pre- existing or active psychiatric or neurologic impairments, not caused by the brain metastasis, which, in the opinion of the investigators, will interfere with the proper administration or completion of the protocol.

  4. Prior Therapy

    • Patients must not have been treated for a previous brain metastasis.
    • Patients must not have had previous cranial radiation.
    • Patients must not undergo treatment with an investigational drug for the primary disease within 7 days of baseline neuropsychological testing.
    • Patients must not receive systemic therapy within 7 days prior to baseline neuropsychological testing.
    • Patients who have had surgery for their current brain metastasis must wait at least 7 days before baseline neuropsychological testing.
  5. Concurrent Therapy

    • Treatment of primary malignancy with systemic therapy (chemotherapy or biologic agents) cannot be delivered concurrently with the treatment of the intracranial disease. However, treatment of the primary site with local therapy, either surgery or radiotherapy, can be performed concurrently with the treatment of the intracranial disease.
    • Patients receiving glucocorticoids should be tapered to the lowest possible dose, or stopped altogether, by the treating physician. If glucocorticoid dose is adjusted or given for the first time, the patient must remain on stable dose of glucocorticoids for at least 24 hours prior to initial neurocognitive testing, CT and MR imaging.
  6. Patients needing emergent radiation therapy for their brain metastases will be excluded.

  7. Patients must not have evidence of leptomeningeal metastases.

  8. Patients must not be HIV positive.

  9. Other medical conditions deemed by the PI or associates to make the patient ineligible for protocol investigations.

  10. Pregnant or breast-feeding females are excluded because of the potential mutagenic effects on a developing fetus or newborn.

  11. Clinically significant unrelated systemic illness which in the judgment of the Principal or Associate Investigator would compromise the patient s ability to tolerate this therapy or are likely to interfere with the study procedures or results.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
1/Cohort 1

KPS>70; Age =65; controlled primary tumor and no extracranial metastases

2/Cohort 2

KPS>70 and at least one of the following: age >65, uncontrolled or synchronous primary disease, or extracranial metastases

3/Cohort 3

KPS<70

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Neuropsychological function
時間枠:Completion of study

To examine the relationship between neuropsychological function and survival in patients receiving radiation therapy for brain metastases

Completion of study
Test scores for: Hopkins Vrbl Learning Test recall; WAIS-III Digit Span; the WAIS-III Symbol Search; the Ruff 2 & 7 Selective Attn. The Trailmaking Tst Part B speed z-score; and the Grooved Pegboard Test dominant hand z-score
時間枠:Completion of study

To identify the neuropsychological test scores which detect significant change in neuropsychological functioning in patients receiving radiation therapy for brain metastases

Completion of study

二次結果の測定

結果測定
メジャーの説明
時間枠
Strengths and weaknesses in neuropsychological functioning
時間枠:completion of study

To examine the strengths and weaknesses in neuropsychological functioning of patients with brain metastases after radiation therapy

completion of study
RTOG RPA classification
時間枠:completion of study

To examine the relationship between the RTOG RPA classification for brain metastasis survival and baseline neuropsychological functioning

completion of study
North American Adult Reading Test-Short Form (NART-35), Hopkins Verbal Learning Test (HVLT), WAIS-III Digit Span subtest, WAIS-III Symbol Search subtest, Ruff 2 and 7 Selective Attention Test
時間枠:completion of study

To further examine whether other measures from the following battery detect significant change in neuropsychological function or predict prognosis in this patient population

completion of study
Neuropsychological functioning, brain lesions (e.g., number and volume), MRI abnormalities, biomarkers, and disease progression or recurrence
時間枠:completion of study

To investigate the relationship between neuropsychological functioning, brain lesions (e.g., number and volume), MRI abnormalities, biomarkers, and disease progression or recurrence

completion of study
Neuropsychological functioning
時間枠:completion of study

To explore the neuropsychological functioning of patients with brain metastases treated with different therapies (e.g. chemotherapy, corticosteroids, complete surgical resection)

completion of study
neuron specific enolase (NSE), S100B, MMPs and VEGF
時間枠:completion of study

To investigate the role of biomarkers, including neuron specific enolase (NSE), S100B, MMPs and VEGF as potential markers of brain injury and disease progression in the serum, plasma and urine of patients with brain metastases

completion of study
Baseline neuropsychological data
時間枠:completion of study

To gather baseline neuropsychological data on patients with brain metastases for use as a reference in the development of new clinical trials involving this patient population in the ROB

completion of study

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:DeeDee K Smart, M.D.、National Cancer Institute (NCI)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2009年4月17日

試験登録日

最初に提出

2011年9月30日

QC基準を満たした最初の提出物

2011年9月30日

最初の投稿 (推定)

2011年10月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年7月14日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 080214
  • 08-C-0214

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All IPD recorded in the medical record will be shared with intramural investigators upon request.

IPD 共有時間枠

Clinical data available during the study and indefinitely.

IPD 共有アクセス基準

Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。